C

    Cyclerion Therapeutics Inc (CYCN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.68
    -0.11 (-2.90%)

    Market Cap: $17.74M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    56%(9/16)
    Avg Surprise
    -97.21%
    Streak
    1 Q
    PeriodReportedEst.SurpriseB/MYoY
    Jun 26
    		$-0.41N/AN/ABeat+26.7%
    Dec 25
    		$-0.19$-0.38+50.00%Beat-191.3%
    Sep 25
    		$-0.30$0.00N/AMiss-4.8%
    Jun 25
    		$-0.11N/AN/ABeat+79.1%
    Mar 25
    		$-0.56N/AN/ABeat+9.6%
    Dec 24
    		$0.21$0.00N/ABeat+130.4%
    Sep 24
    		$-0.29$0.00N/ABeat-109.2%
    Jun 24
    		$-0.53$0.00N/ABeat+71.3%
    Mar 24
    		$-0.62$0.00N/ABeat+80.7%
    Dec 23
    		$-0.68$0.00N/ABeat-302.8%
    Sep 23
    		$3.11N/AN/ABeat+164.7%
    Jun 23
    		$-1.83$-0.28-554.36%Miss+70.4%
    Mar 23
    		$-3.20$-0.30-965.23%Miss+46.7%
    Dec 22
    		$-0.17$-0.29+41.38%Beat+48.5%
    Sep 22
    		$-4.80$-7.00+31.43%Beat+7.7%
    Jun 22
    		$-6.20$-6.80+8.82%Beat-1277.8%
    Mar 22
    		$-6.00$-7.20+16.67%Beat-1438.5%
    Dec 21
    		$-0.33$-0.30-10.00%Miss+97.0%
    Sep 21
    		$-5.20$-5.80+10.34%Beat+55.9%
    Jun 21
    		$-0.45$0.00N/ABeat+96.8%
    Mar 21
    		$-0.39$0.00N/ABeat+46.6%
    Dec 20
    		$-11.00$-3.80-189.47%Miss+42.1%
    Sep 20
    		$-11.80$-11.20-5.36%Miss+41.0%
    Jun 20
    		$-14.00$-17.26+18.89%Beat+40.7%
    Mar 20
    		$-0.73$-0.87+16.09%Beat+20.7%
    Dec 19
    		$-19.00$-17.84-6.50%Miss-854.8%
    Sep 19
    		$-20.00$-25.98+23.02%Beat-465.0%
    Jun 19
    		$-23.60$-16.72-41.15%Miss-
    Mar 19
    		$-0.92N/AN/ABeat-
    Dec 18
    		$-1.99$0.00N/AMiss-
    Sep 18
    		$-3.54$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-3.64EV/EBITDA0.56x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-359.20%
    ROE-98.20%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio0.82xQuick Ratio0.82x
    Trading Statistics
    Beta1.75Avg Volume51.79K
    52-Week High$8.4852-Week Low$1.03

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$3.98
    SMA 20$3.84
    SMA 50$3.65
    SMA 200$2.49
    EMA 10$3.89
    EMA 20$3.84
    EMA 50$3.64
    EMA 200$2.93

    MACD

    Line: 0.09Signal: 0.12Hist: -0.03

    ADX

    ADX: 37.5+DI: 20.3-DI: 14.9

    Aroon & PSAR

    Aroon Up72.0
    Aroon Down16.0
    PSAR$4.45

    Bollinger Bands

    Upper Band$4.28
    Lower Band$3.39
    %B Position2310%(Upper)
    Band Width0.32

    RSI (14-Day)

    Neutral
    45.3

    Momentum Oscillators

    Stoch %K35.9
    Stoch %D50.1
    Williams %R-84.0
    ROC (10d)-8.7%
    Momentum-0.35
    CCI (20d)-53.5
    MFI (14d)51.3

    Volatility Measures

    ATR (14d)$0.34(9.3%)
    StdDev (20d)0.22
    Hist Vol56.3%(High)

    Volume Flow

    VWAP$3.71
    OBV348.6M
    AD Line-119.6M
    CMF (20d)-0.396

    Volume Metrics

    Avg Vol (20d)54.1K
    Vol Ratio3.1x(High)
    VWMA (20d)$3.89

    Pivot Points

    R3$4.64
    R2$4.46
    R1$4.12
    Pivot Point$3.94
    S1$3.60
    S2$3.42
    S3$3.08

    Advanced Oscillators

    TSI15.91
    Ultimate Osc26.6
    KST108.25

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$1.20M$875,000$93,000$81,000$1.81M$194,000$0$0$0$0
    Cost of Revenue$0$0N/A$0$0$0N/A$0$0$0N/A$0
    Gross Profit$0$0$1.20M$875,000$93,000$81,000$1.81M$194,000$0$0N/A$0
    Operating Expenses$1.77M$3.21M$1.86M$1.88M$1.76M$1.54M$1.30M$1.32M$1.38M$1.62M$1.80M$6.01M
    R&D$0$730,000$519,000$348,000$56,000$36,000$56,000$81,000$105,000$44,000$24,000$580,000
    SG&A$1.77M$2.48M$1.34M$1.53M$1.71M$1.50M$1.25M$1.24M$1.28M$1.57M$1.77M$2.13M
    Operating Income$-1,771,000$-3,209,000$-838,000$-1,006,000$-1,672,000$-1,457,000$502,000$-1,128,000$-1,384,000$-1,618,000$-1,796,000$-6,015,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-1,755,000$-3,177,000$692,000$-976,000$-324,000$-1,429,000$530,000$-723,000$-1,322,000$-1,542,000$-1,545,000$-5,908,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-1,755,000$-3,177,000$-799,000$-976,000$-324,000$-1,429,000$530,000$-723,000$-1,322,000$-1,542,000$-1,694,000$7.57M
    EBITDA$-1,755,000$-3,177,000$518,000$-976,000$-324,000$-1,429,000$530,000$-723,000$-1,322,000$-1,542,000$-1,796,000$-5,908,000
    EBIT$-1,755,000$-3,177,000$518,000$-976,000$-324,000$-1,429,000$530,000$-723,000$-1,322,000$-1,542,000$-1,796,000$-5,908,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CYCN

    News

    Cyclerion Therapeutics - Sets Sept 4, 2026 As Record Date For Cvr Distribution In Korsana Merger - SEC Filing

    Cyclerion Therapeutics announced that it has set September 4, 2026, as the record date for the Contingent Value Right (CVR) distribution in connection with its merger with Korsana. This information was disclosed in an SEC filing.

    TradingView•8/25/26•
    Neutral

    Cyclerion Therapeutics (CYCN) sets CVR date for Korsana merger

    Cyclerion Therapeutics (CYCN) has announced that September 4, 2026, will be the record date for the distribution of contingent value rights (CVRs) to shareholders in connection with its planned merger with Korsana Biosciences, Inc. The company highlighted various risks associated with the merger, including the need for shareholder approval, financing, regulatory hurdles, and potential legal proceedings. Investors are advised to review the Form S-4 and related proxy statement/prospectus for detailed information regarding the transaction and CVRs.

    Stock Titan•8/25/26•
    Neutral

    Cyclerion (NASDAQ: CYCN) CFO buys 25,000 shares in cash exercise

    Cyclerion Therapeutics, Inc.'s Chief Financial Officer, Rhonda M. Chicko, exercised options to purchase 25,000 shares of common stock at an exercise price of $2.355 per share. The options were granted in August 2025, and their vesting was fully accelerated by the board on July 17, 2026. Following this cash exercise, Chicko directly holds 25,018 shares of CYCN common stock.

    Stock Titan•8/18/26•
    Neutral

    Cyclerion (CYCN) CEO uses cashless exercise, forfeits 48,629 options

    Cyclerion Therapeutics, Inc. CEO Regina Margaret Graul exercised an employee stock option for 55,849 shares at $3.30 per share on August 14, 2026. This was a cashless exercise where 48,629 shares were forfeited to cover the exercise price, resulting in a net acquisition of 7,220 shares. The option's vesting was fully accelerated by the board on July 17, 2026, ahead of its original schedule.

    Stock Titan•8/18/26•
    Neutral

    Cyclerion Therapeutics (CYCN): ADAR1 Capital discloses 7.0% beneficial ownership

    ADAR1 Capital Management, LLC and Daniel Schneeberger have reported beneficial ownership of 7.0% of Cyclerion Therapeutics, Inc. (CYCN) common stock, totaling 298,757 shares. This ownership is held by private investment funds managed by ADAR1, with both reporting persons exercising shared voting and dispositive power. The disclosure is based on 4,256,284 shares of Cyclerion common stock outstanding as of June 30, 2026.

    Stock Titan•8/15/26•
    Neutral

    Frequently Asked Questions About CYCN

    Does CYCN pay dividends?
    Cyclerion Therapeutics Inc (CYCN) does not currently pay a regular dividend.
    What is CYCN's market cap?
    Cyclerion Therapeutics Inc (CYCN) has a market capitalization of $17.74M with a current stock price of $3.68.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In